Literature DB >> 25982799

Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target?

Manyi Ren1, Xiuzhen Li, Li Hao, Jingquan Zhong.   

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice and a major cause of morbidity and mortality. Although the fundamental mechanisms underlying AF remain incompletely understood, atrial remodeling, including structural, electrical, contractile, and autonomic remodeling, has been demonstrated to contribute to the substrate for AF maintenance. Accumulating evidence shows that tumor necrosis factor alpha (TNF-α) plays exceedingly important roles in atrial remodeling. This article reviews recent advances in the roles of TNF-α in the pathogenesis of AF, elucidates the related mechanisms, and exploits its potential usefulness as a novel therapeutic target.

Entities:  

Keywords:  Atrial fibrillation; atrial fibrosis; remodeling; therapy; tumor necrosis factor alpha

Mesh:

Substances:

Year:  2015        PMID: 25982799     DOI: 10.3109/07853890.2015.1042030

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  13 in total

Review 1.  Role of inflammatory signaling in atrial fibrillation.

Authors:  Larry Scott; Na Li; Dobromir Dobrev
Journal:  Int J Cardiol       Date:  2018-10-04       Impact factor: 4.164

2.  Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation.

Authors:  Yanan Chu; Fangcong Yu; Yakui Wu; Jinxiu Yang; Jiaran Shi; Tianxin Ye; Deheng Han; Xingxiang Wang
Journal:  BMC Med Genomics       Date:  2022-07-05       Impact factor: 3.622

3.  Bidirectional Association Between Kidney Function and Atrial Fibrillation: A Population-Based Cohort Study.

Authors:  Anna C van der Burgh; Sven Geurts; M Arfan Ikram; Ewout J Hoorn; Maryam Kavousi; Layal Chaker
Journal:  J Am Heart Assoc       Date:  2022-05-17       Impact factor: 6.106

4.  Risk factors, thromboembolic events, and clinical course of New-Onset Atrial Fibrillation among COVID-19 hospitalized patients: A multicenter cross-sectional analysis in Iran.

Authors:  Fatemeh Sadat Rahimi; Siamak Afaghi; Farzad Esmaeili Tarki; Hossein Salehi Omran; Mohammad Hossein Nasirpour
Journal:  Health Sci Rep       Date:  2022-10-17

Review 5.  Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology Of Atrial Fibrillation.

Authors:  Saira Rafaqat; Saima Sharif; Mona Majeed; Shagufta Naz; Farkhanda Manzoor; Sana Rafaqat
Journal:  J Atr Fibrillation       Date:  2021-08-31

6.  Inflammatory activation and endothelial dysfunction markers in patients with permanent atrial fibrillation: a cross-sectional study.

Authors:  Carlo Domenico Maida; Sonya Vasto; Domenico Di Raimondo; Alessandra Casuccio; Valerio Vassallo; Mario Daidone; Alessandro Del Cuore; Gaetano Pacinella; Anna Cirrincione; Irene Simonetta; Vittoriano Della Corte; Salvatore Rizzica; Giulio Geraci; Antonino Tuttolomondo; Antonio Pinto
Journal:  Aging (Albany NY)       Date:  2020-05-03       Impact factor: 5.682

Review 7.  Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge.

Authors:  Nso Nso; Kaveh R Bookani; Mark Metzl; Farshid Radparvar
Journal:  J Arrhythm       Date:  2020-12-23

Review 8.  Role of Monocytes in Heart Failure and Atrial Fibrillation.

Authors:  Farhan Shahid; Gregory Y H Lip; Eduard Shantsila
Journal:  J Am Heart Assoc       Date:  2018-02-01       Impact factor: 5.501

9.  Selective blocking of CXCR2 prevents and reverses atrial fibrillation in spontaneously hypertensive rats.

Authors:  Yun-Long Zhang; Fei Teng; Xiao Han; Pang-Bo Li; Xiao Yan; Shu-Bin Guo; Hui-Hua Li
Journal:  J Cell Mol Med       Date:  2020-08-18       Impact factor: 5.310

10.  The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.

Authors:  Takao Sato; Yoshifusa Aizawa; Sho Yuasa; Satoshi Fujita; Yoshio Ikeda; Masaaki Okabe
Journal:  J Atheroscler Thromb       Date:  2020-02-28       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.